secwatch.observer — SEC 8-K summary
======================================

Issuer:     ArriVent BioPharma, Inc. (AVBP)
CIK:        0001868279
Form:       8-K
Filed at:   2026-05-11T20:43:06+00:00
Accession:  0001104659-26-058706
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ArriVent BioPharma expands at-the-market equity program by up to $250M
----------------------------------------------------------------------

- Filed prospectus supplement on May 11, 2026 to sell up to $250,000,000 of common stock via ATM.
- Jefferies LLC named as sales agent under existing Open Market Sale Agreement dated Feb 3, 2025.
- Proceeds will be used for general corporate purposes; no specific use disclosed.
- Offering is made under automatic shelf registration statement (Form S-3ASR, File 333-284661).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1868279/000110465926058706/0001104659-26-058706-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1868279/000110465926058706/tm2614177d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-058706

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer